timothy sykes logo

Stock News

ImmunityBio’s Strategic Moves Spark Global Interest

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 1/13/2026, 11:33 am ET 1/13/2026, 11:33 am ET | 4 min 4 min read
ImmunityBio’s Strategic Moves Spark Global Interest Thumbnail

ImmunityBio Inc.’s stocks have been trading up by 9.07 percent amid FDA approvals and promising studies boosting investor optimism.

Candlestick Chart

Live Update At 11:32:53 EST: On Tuesday, January 13, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 9.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview

ImmunityBio, Inc. (IBRX) has been demonstrating significant momentum lately, with impressive advances in the field of cancer treatment. Recent data revealed breakthrough success of their product Anktiva, when combined with the BCG vaccine, achieving a remarkable bladder cancer-specific survival rate of 96% over three years. Such therapeutic efficacy marks a notable milestone in the field where options are scarce.

Looking at the financials, recent trading data indicates a steady upward trajectory, reflecting the positive market reception to these announcements. On Jan 13, 2026, IBRX stock opened at $2.68 and closed at $2.825, displaying investor confidence in the company’s innovative endeavors. This increase comes against the backdrop of a challenging financial landscape, highlighting the resilience and potential investors see in ImmunityBio’s strategy.

In financial terms, the company reported revenue of $14.75M, though key ratios reveal substantial hurdles with operating margins and profitability measures showing negative figures. However, with an enterprise value soaring to an impressive $5.27B, there’s an overwhelming market belief in future growth prospects, particularly with expansion into underserved medical territories.

Market Reactions

The buzz surrounding ImmunityBio stems not only from successful trials but also from strategic leadership moves. Dr. Patrick Soon-Shiong’s recognition as a key influencer in oncology cements the company’s reputation as a forefront innovator. His leadership is seen as pivotal, steering the organization towards a future where cancer might be a problem of the past.

Global engagements further amplify the company’s reach, with the U.S.-Saudi Biotech Alliance Summit designed to maximize collaborative opportunities. This summit targets not just advanced research paths but also the potential for infectious disease prevention — a timely concern given the global health landscape. Such initiatives are significant, reflecting the company’s forward-thinking strategies.

More Breaking News

Conclusion

In summary, ImmunityBio is at a compelling juncture. Despite difficult financial metrics, their strategic wins in medical achievements and collaborative initiatives set a promising stage for the future. The company’s stock is enjoying a rally fueled by optimistic announcements, opening new chapters in the biotech field. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” This mantra resonates with traders rallying behind initiatives that not only promise returns but champion life-saving innovations. As ImmunityBio forges new alliances and wins high-stakes endorsements, the markets will be watching this unfolding story with bated breath.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”